BridgeBio Pharma said on Tuesday it will stop development of its experimental therapy for a genetic disease that affects the adrenaline-producing gland.
The drugmaker said the results of its early-to-mid stage study testing the therapy did not meet the threshold to warrant additional capital investment.
https://kfgo.com/2024/09/10/bridgebio-to-stop-development-of-therapy-for-genetic-disorder/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.